Targeting glutamine induces apoptosis: A cancer therapy approach

International Journal of Molecular Sciences

Volumn 16, Issue 9, 2015, Pages 22830-22855

  Chen, Lian ^a   Cui, Hengmin ^a  

^a SICHUAN AGRICULTURAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cancer; Glutaminase; Glutamine metabolism

Indexed keywords

GLUCOSE TRANSPORTER; GLUTAMINASE; GLUTAMINE; HYPOXIA INDUCIBLE FACTOR; OXOGLUTARATE DEHYDROGENASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; RAS PROTEIN; ENZYME INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1; MYC PROTEIN;

AMINO ACID METABOLISM; APOPTOSIS; AUTOPHAGY; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CITRIC ACID CYCLE; DRUG TARGETING; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GLYCOLYSIS; HUMAN; HYPOXIA; KWASHIORKOR; OXIDATIVE PHOSPHORYLATION; OXYGEN TISSUE LEVEL; PROTEIN METABOLISM; PROTEIN TRANSPORT; PROTO ONCOGENE; REGULATOR GENE; REGULATORY MECHANISM; REVIEW; TRANSLATION INITIATION; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; APOPTOSIS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMINASE; GLUTAMINE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; RAS PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84942162875     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160922830     Document Type: Review

References (142)

1. Bergstrom, J.; Furst, P.; Noree, L.O.; Vinnars, E. Intracellular free amino acid concentration in human muscle tissue. J. Appl. Physiol. 1974, 36, 693–697.
2. Mohamed, A.; Deng, X.; Khuri, F.R.; Owonikoko, T.K. Altered glutamine metabolism and therapeutic opportunities for lung cancer. Clin. Lung Cancer 2014, 15, 7–15.
3. Fuchs, B.C.; Bode, B.P. Stressing out over survival: Glutamine as an apoptotic modulator. J. Surg. Res. 2006, 131, 26–40.
4. Ko, Y.G.; Kim, E.Y.; Kim, T.; Park, H.; Park, H.S.; Choi, E.J.; Kim, S. Glutamine-dependent antiapoptotic interaction of human glutaminyl-tRNA synthetase with apoptosis signal-regulating kinase 1. J. Biol. Chem. 2001, 276, 6030–6036.
5. Lora, J.; Alonso, F.J.; Segura, J.A.; Lobo, C.; Marquez, J.; Mates, J.M. Antisense glutaminase inhibition decreases glutathione antioxidant capacity and increases apoptosis in Ehrlich ascitic tumour cells. Eur. J. Biochem. 2004, 271, 4298–4306.
6. Hensley, C.T.; Wasti, A.T.; DeBerardinis, R.J. Glutamine and cancer: Cell biology, physiology, and clinical opportunities. J. Clin. Investig. 2013, 123, 3678–3684.
7. Rajendram, D.R.; Preedy, V.R.; Patel, V.B. Glutamine in Clinical Nutrition; Springer: Berlin, Germany, 2014.
8. Daye, D.; Wellen, K.E. Metabolic reprogramming in cancer: Unraveling the role of glutamine in tumorigenesis. Semin. Cell Dev. Biol. 2012, 23, 362–369.
9. DeBerardinis, R.J.; Mancuso, A.; Daikhin, E.; Nissim, I.; Yudkoff, M.; Wehrli, S.; Thompson, C.B. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl. Acad. Sci. USA 2007, 104, 19345–19350.
10. DeBerardinis, R.J.; Cheng, T. Q’s next: The diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2009, 29, 313–324.
11. Warburg, O.; Wind, F.; Negelein, E. The metabolism of tumors in the body. J. Gen. Physiol. 1927, 8, 519–530.
12. Zhdanov, A.V.; Waters, A.H.; Golubeva, A.V.; Dmitriev, R.I.; Papkovsky, D.B. Availability of the key metabolic substrates dictates the respiratory response of cancer cells to the mitochondrial uncoupling. Biochim. Biophys. Acta 2014, 1837, 51–62.
13. Gonzalez Herrera, K.N.; Lee, J.; Haigis, M.C. Intersections between mitochondrial sirtuin signaling and tumor cell metabolism. Crit. Rev. Biochem. Mol. Biol. 2015, 50, 242–255.
14. Wise, D.R.; Thompson, C.B. Glutamine addiction: A new therapeutic target in cancer. Trends Biochem. Sci. 2010, 35, 427–433.
15. Gross, M.I.; Demo, S.D.; Dennison, J.B.; Chen, L.; Chernov-Rogan, T.; Goyal, B.; Janes, J.R.; Laidig, G.J.; Lewis, E.R.; Li, J et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol. Cancer Ther. 2014, 13, 890–901.
16. Qing, G.; Li, B.; Vu, A.; Skuli, N.; Walton, Z.E.; Liu, X.; Mayes, P.A.; Wise, D.R.; Thompson, C.B.; Maris, J.M. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell 2012, 22, 631–644.
17. Medina, M.A.; Sánchez-Jiménez, F.; Márquez, J.; Quesada, A.R.; de Castro Núñez, I. Relevance of glutamine metabolism to tumor cell growth. Mol. Cell. Biochem. 1992, 113, 1–15.
18. Fuchs, B.C.; Bode, B.P. Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime? Semin. Cancer Biol. 2005, 15, 254–266.
19. Bröer, S. Adaptation of plasma membrane amino acid transport mechanisms to physiological demands. Pflügers Arch. 2002, 444, 457–466.
20. Dolińska, M.; Dybel, A.; Zabłocka, B.; Albrecht, J. Glutamine transport in C6 glioma cells shows ASCT2 system characteristics. Neurochem. Int. 2003, 43, 501–507.
21. Wasa, M.; Wang, H.-S.; Okada, A. Characterization of L-glutamine transport by a human neuroblastoma cell line. Am. J. Physiol. Cell Physiol. 2002, 282, C1246–C1253.
22. Kron, C.; Bode, B. Glutamine transporter expression profiling reveal major role for ASCT2 and LAT1 in primary and metastatic human hepatocellular carcinoma cells. FASEB J. 2015, 29, doi:10.1096/fj.1530-6860.
23. Shimizu, K.; Kaira, K.; Tomizawa, Y.; Sunaga, N.; Kawashima, O.; Oriuchi, N.; Kana, Y.; Yamada, M.; Oyama, T.; Takeyoshi, I. P0143 ASC amino acid transporter 2 (ASCT2) as a novel prognostic marker in non-small-cell lung cancer. Eur. J. Cancer 2014, 50, e49, doi:10.1016/j.ejca.2014.03.187.
24. Jeon, Y.J.; Khelifa, S.; Feng, Y.; Lau, E.; Cardiff, R.; Kim, H.; Rimm, D.L.; Kluger, Y.; Ronai, Z.E. RNF5 mediates ER stress-induced degradation of SLC1A5 in breast cancer. Cancer Res. 2014, 74, 2440.
25. Cheng, T.; Sudderth, J.; Yang, C.; Mullen, A.R.; Jin, E.S.; Matés, J.M.; DeBerardinis, R.J. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc. Natl. Acad. Sci. 2011, 108, 8674–8679.
26. Dang, C.V.; O’Donnell, K.A.; Zeller, K.I.; Nguyen, T.; Osthus, R.C.; Li, F. The c-Myc target gene network. Semin. Cancer Biol. 2006, 16, 253–264.
27. Lutz, W.; Stöhr, M.; Schürmann, J.; Wenzel, A.; Löhr, A.; Schwab, M. Conditional expression of N-myc in human neuroblastoma cells increases expression of α-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 1996, 13, 803–812.
28. Vita, M.; Henriksson, M. The Myc oncoprotein as a therapeutic target for human cancer. Semin. Cancer Biol. 2006, 16, 318–330.
29. Rudolph, C.; Adam, G.; Simm, A. Determination of copy number of c-Myc protein per cell by quantitative Western blotting. Anal. Biochem. 1999, 269, 66–71.
30. Wise, D.R.; DeBerardinis, R.J.; Mancuso, A.; Sayed, N.; Zhang, X.-Y.; Pfeiffer, H.K.; Nissim, I.; Daikhin, E.; Yudkoff, M.; McMahon, S.B. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. USA 2008, 105, 18782–18787.
31. Gao, P.; Tchernyshyov, I.; Chang, T.-C.; Lee, Y.-S.; Kita, K.; Ochi, T.; Zeller, K.I.; de Marzo, A.M.; van Eyk, J.E.; Mendell, J.T. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009, 458, 762–765.
32. Yuneva, M.O.; Fan, T.W.; Allen, T.D.; Higashi, R.M.; Ferraris, D.V.; Tsukamoto, T.; Matés, J.M.; Alonso, F.J.; Wang, C.; Seo, Y. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 2012, 15, 157–170.
33. Veas-Perez de Tudela, M.; Delgado-Esteban, M.; Cuende, J.; Bolanos, J.P.; Almeida, A. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase. J. Neurochem. 2010, 113, 819–825.
34. Westermark, U.K.; Wilhelm, M.; Frenzel, A.; Henriksson, M.A. The MYCN oncogene and differentiation in neuroblastoma. Semin. Cancer Biol. 2011, 21, 256–266.
35. Felsher, D.W. MYC inactivation elicits oncogene addiction through both tumor cell-intrinsic and host-dependent mechanisms. Genes Cancer 2010, 1, 597–604.
36. Kruspig, B.; Nilchian, A.; Bejarano, I.; Orrenius, S.; Zhivotovsky, B.; Gogvadze, V. Targeting mitochondria by α-tocopheryl succinate kills neuroblastoma cells irrespective of MycN oncogene expression. Cell. Mol. Life Sci. 2012, 69, 2091–2099.
37. Yamaguchi, Y.; Takenobu, H.; Ohira, M.; Nakazawa, A.; Yoshida, S.; Akita, N.; Shimozato, O.; Iwama, A.; Nakagawara, A.; Kamijo, T. Novel 1p tumour suppressor Dnmt1-associated protein 1 regulates MYCN/ataxia telangiectasia mutated/p53 pathway. Eur. J. Cancer 2014, 50, 1555–1565.
38. Jackson, J.; Lozano, G. The mutant p53 mouse as a pre-clinical model. Oncogene 2013, 32, 4325–4330.
39. Sherr, C.J.; McCormick, F. The RB and p53 pathways in cancer. Cancer Cell 2002, 2, 103–112.
40. Nieminen, A.I.; Eskelinen, V.M.; Haikala, H.M.; Tervonen, T.A.; Yan, Y.; Partanen, J.I.; Klefstrom, J. Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis. Proc. Natl. Acad. Sci. USA 2013, 110, E1839–E1848.
41. Lane, D.; Levine, A. p53 Research: The past thirty years and the next thirty years. Cold Spring Harb. Perspect. Biol. 2010, 2, a000893.
42. Hu, W.; Zhang, C.; Wu, R.; Sun, Y.; Levine, A.; Feng, Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc. Natl. Acad. Sci. USA 2010, 107, 7455–7460.
43. Suzuki, S.; Tanaka, T.; Poyurovsky, M.V.; Nagano, H.; Mayama, T.; Ohkubo, S.; Lokshin, M.; Hosokawa, H.; Nakayama, T.; Suzuki, Y. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc. Natl. Acad. Sci. USA 2010, 107, 7461–7466.
44. Jiang, L.; Kon, N.; Li, T.; Wang, S.-J.; Su, T.; Hibshoosh, H.; Baer, R.; Gu, W. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 2015, 520, 57–62.
45. Lo, M.; Wang, Y.Z.; Gout, P.W. The xc- cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases. J. Cell. Physiol. 2008, 215, 593–602.
46. Levine, A.J.; Puzio-Kuter, A.M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010, 330, 1340–1344.
47. Gaglio, D.; Metallo, C.M.; Gameiro, P.A.; Hiller, K.; Danna, L.S.; Balestrieri, C.; Alberghina, L.; Stephanopoulos, G.; Chiaradonna, F. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol. Syst. Biol. 2011, 7, 523.
48. White, E. Exploiting the bad eating habits of Ras-driven cancers. Genes Dev. 2013, 27, 2065–2071.
49. Ying, H.; Kimmelman, A.C.; Lyssiotis, C.A.; Hua, S.; Chu, G.C.; Fletcher-Sananikone, E.; Locasale, J.W.; Son, J.; Zhang, H.; Coloff, J.L. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012, 149, 656–670.
50. Son, J.; Lyssiotis, C.A.; Ying, H.; Wang, X.; Hua, S.; Ligorio, M.; Perera, R.M.; Ferrone, C.R.; Mullarky, E.; Shyh-Chang, N. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013, 496, 101–105.
51. Gaglio, D.; Soldati, C.; Vanoni, M.; Alberghina, L.; Chiaradonna, F. Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts. PLoS ONE 2009, 4, e4715.
52. Chen, J.Q.; Russo, J. Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells. Biochim. Biophys. Acta 2012, 1826, 370–384.
53. MacKenzie, E.D.; Selak, M.A.; Tennant, D.A.; Payne, L.J.; Crosby, S.; Frederiksen, C.M.; Watson, D.G.; Gottlieb, E. Cell-permeating α-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol. Cell. Biol. 2007, 27, 3282–3289.
54. Papandreou, I.; Cairns, R.A.; Fontana, L.; Lim, A.L.; Denko, N.C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006, 3, 187–197.
55. Le, A.; Lane, A.N.; Hamaker, M.; Bose, S.; Gouw, A.; Barbi, J.; Tsukamoto, T.; Rojas, C.J.; Slusher, B.S.; Zhang, H. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 2012, 15, 110–121.
56. Zhao, Y.; Butler, E.; Tan, M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013, 4, e532.
57. Cassago, A.; Ferreira, A.P.; Ferreira, I.M.; Fornezari, C.; Gomes, E.R.; Greene, K.S.; Pereira, H.M.; Garratt, R.C.; Dias, S.M.; Ambrosio, A.L. Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism. Proc. Natl. Acad. Sci. USA 2012, 109, 1092–1097.
58. Sun, R.C.; Denko, N.C. Hypoxic regulation of glutamine metabolism through HIF 1 and SIAH2 supports lipid synthesis that is necessary fot tumor growth. Cell Metab. 2014, 19, 285–292.
59. Metallo, C.M.; Gameiro, P.A.; Bell, E.L.; Mattaini, K.R.; Yang, J.; Hiller, K.; Jewell, C.M.; Johnson, Z.R.; Irvine, D.J.; Guarente, L et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2012, 481, 380–384.
60. Faubert, B.; Vincent, E.E.; Griss, T.; Samborska, B.; Izreig, S.; Svensson, R.U.; Mamer, O.A.; Avizonis, D.; Shackelford, D.B.; Shaw, R.J et al. Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α. Proc. Natl. Acad. Sci. USA 2014, 111, 2554–2559.
61. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674.
62. Matés, J.M.; Segura, J.A.; Alonso, F.J.; Márquez, J. Pathways from glutamine to apoptosis. Front. Biosci. 2006, 11, 3164–3180.
63. Petronini, P.G.; Urbani, S.; Alfieri, R.; Borghetti, A.F.; Guidotti, G.G. Cell susceptibility to apoptosis by glutamine deprivation and rescue: Survival and apoptotic death in cultured lymphoma-leukemia cell lines. J. Cell. Physiol. 1996, 169, 175–185.
64. Oehler, R.; Pusch, E.; Dungel, P.; Zellner, M.; Eliasen, M.M.; Brabec, M.; Roth, E. Glutamine depletion impairs cellular stress response in human leucocytes. Br. J. Nutr. 2002, 87, S17–S21.
65. Jäättelä, M.; Wissing, D.; Kokholm, K.; Kallunki, T.; Egeblad, M. Hsp70 exerts its anti-apoptotic function downstream of caspase 3-like proteases. EMBO J. 1998, 17, 6124–6134.
66. Paquette, J.C.; Guérin, P.J.; Gauthier, E.R. Rapid induction of the intrinsic apoptotic pathway by L-glutamine starvation. J. Cell. Physiol. 2005, 202, 912–921.
67. Fuchs, B.C.; Perez, J.C.; Suetterlin, J.E.; Chaudhry, S.B.; Bode, B.P. Inducible antisense RNA targeting amino acid transporter ATB0/ASCT2 elicits apoptosis in human hepatoma cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 286, G467–G478.
68. Robert, S.M.; Sontheimer, H. Glutamate transporters in the biology of malignant gliomas. Cell. Mol. Life Sci. 2014, 71, 1839–1854.
69. Ortega, A.L.; Carretero, J.; Obrador, E.; Gambini, J.; Asensi, M.; Rodilla, V.; Estrela, J.M. Tumor cytotoxicity by endothelial cells impairment of the mitochondrial system for glutathione uptake in mouse b16 melanoma cells that survive after in vitrointeraction with the hepatic sinusoidal endothelium. J. Biol. Chem. 2003, 278, 13888–13897.
70. Reid, M.A.; Wang, W.-I.; Rosales, K.R.; Welliver, M.X.; Pan, M.; Kong, M. The B55α subunit of PP2A drives a p53-dependent metabolic adaptation to glutamine deprivation. Mol. Cell 2013, 50, 200–211.
71. Griffith, O.W. Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic. Biol. Med. 1999, 27, 922–935.
72. Cardaci, S.; Rizza, S.; Filomeni, G.; Bernardini, R.; Bertocchi, F.; Mattei, M.; Paci, M.; Rotilio, G.; Ciriolo, M.R. Glutamine deprivation enhances antitumor activity of 3-bromopyruvate through the stabilization of monocarboxylate transporter-1. Cancer Res. 2012, 72, 4526–4536.
73. Zhao, Y.; Li, X.; Cai, M.-Y.; Ma, K.; Yang, J.; Zhou, J.; Fu, W.; Wei, F.-Z.; Wang, L.; Xie, D. XBP-1u suppresses autophagy by promoting the degradation of FoxO1 in cancer cells. Cell Res. 2013, 23, 491–507.
74. Abcouwer, S.F.; Schwarz, C.; Meguid, R.A. Glutamine deprivation induces the expression of GADD45 and GADD153 primarily by mRNA stabilization. J. Biol. Chem. 1999, 274, 28645–28651.
75. Desideri, E.; Ciriolo, M.R. Glutamine addiction of cancer cells. In Glutamine in Clinical Nutrition; Springer: Berlin, Germany, 2015; pp. 99–111.
76. Sidoryk, M.; Matyja, E.; Dybel, A.; Zielinska, M.; Bogucki, J.; Jaskolski, D.J.; Liberski, P.P.; Kowalczyk, P.; Albrecht, J. Increased expression of a glutamine transporter SNAT3 is a marker of malignant gliomas. Neuroreport 2004, 15, 575–578.
77. Todorova, V.K.; Kaufmann, Y.; Luo, S.; Klimberg, V.S. Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake. Cancer Chemother. Pharmacol. 2011, 67, 285–291.
78. Wang, Q.; Hardie, R.A.; Hoy, A.J.; van Geldermalsen, M.; Gao, D.; Fazli, L.; Sadowski, M.C.; Balaban, S.; Schreuder, M.; Nagarajah, R et al. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. J. Pathol. 2015, 236, 278–289.
79. Imai, H.; Kaira, K.; Oriuchi, N.; Shimizu, K.; Tominaga, H.; Yanagitani, N.; Sunaga, N.; Ishizuka, T.; Nagamori, S.; Promchan, K. Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. Anticancer Res. 2010, 30, 4819–4828.
80. Janpipatkul, K.; Suksen, K.; Borwornpinyo, S.; Jearawiriyapaisarn, N.; Hongeng, S.; Piyachaturawat, P.; Chairoungdua, A. Downregulation of LAT1 expression suppresses cholangiocarcinoma cell invasion and migration. Cell Signal. 2014, 26, 1668–1679.
81. Timmerman, L.A.; Holton, T.; Yuneva, M.; Louie, R.J.; Padro, M.; Daemen, A.; Hu, M.; Chan, D.A.; Ethier, S.P.; van’t Veer, L.J et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 2013, 24, 450–465.
82. Goossens, V.; Grooten, J.; Fiers, W. The oxidative metabolism of glutamine A modulator of reactive oxygen intermediate-mediated cytotoxicity of tumor necrosis factor in L929 fibrosarcoma cells. J. Biol. Chem. 1996, 271, 192–196.
83. Liu, S.-L.; Shi, D.-Y.; Shen, Z.-H.; Wu, Y.-D. Effects of glutamine on tumor growth and apoptosis of hepatoma cells. Acta Pharmacol. Sin. 2000, 21, 668–672.
84. Hartwick, E.W.; Curthoys, N.P. BPTES inhibition of hGA124–551, a truncated form of human kidney-type glutaminase. J. Enzym. Inhib. Med. Chem. 2012, 27, 861–867.
85. Katt, W.P.; Cerione, R.A. Glutaminase regulation in cancer cells: A druggable chain of events. Drug Discov. Today 2014, 19, 450–457.
86. DeLaBarre, B.; Gross, S.; Fang, C.; Gao, Y.; Jha, A.; Jiang, F.; Song J.J.; Wei, W.; Hurov, J.B. Full-length human glutaminase in complex with an allosteric inhibitor. Biochemistry 2011, 50, 10764–10770.
87. Thangavelu, K.; Pan, C.Q.; Karlberg, T.; Balaji, G.; Uttamchandani, M.; Suresh, V.; Schüler, H.; Low, B.C.; Sivaraman, J. Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism. Proc. Natl. Acad. Sci. USA 2012, 109, 7705–7710.
88. Kvamme, E.; Nissen-Meyer, L.S.H.; Roberg, B.Å.; Torgner, I.A. Novel form of phosphate activated glutaminase in cultured astrocytes and human neuroblastoma cells, PAG in brain pathology and localization in the mitochondria. Neurochem. Res. 2008, 33, 1341–1345.
89. Thangavelu, K.; Chong, Q.Y.; Low, B.C.; Sivaraman, J. Structural basis for the active site inhibition mechanism of human kidney-type glutaminase (KGA). Sci. Rep. 2014, 4, 3827.
90. Wang, J.-B.; Erickson, J.W.; Fuji, R.; Ramachandran, S.; Gao, P.; Dinavahi, R.; Wilson, K.F.; Ambrosio, A.L.; Dias, S.M.; Dang, C.V. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010, 18, 207–219.
91. Erickson, J.W.; Cerione, R.A. Glutaminase: A hot spot for regulation of cancer cell metabolism? Oncotarget 2010, 1, 734–740.
92. Stalnecker, C.; Erickson, J.; Ramachandran, S.; DeBerardinis, R.; Cerione, R. Abstract C42: Mitochondrial glutaminase regulation and small molecule inhibition of glutamine metabolism. Cancer Res. 2013, 73, C42.
93. Wilson, K.F.; Erickson, J.W.; Antonyak, M.A.; Cerione, R.A. Rho GTPases and their roles in cancer metabolism. Trends Mol. Med. 2013, 19, 74–82.
94. Matre, P.; Shariati, M.; Velez, J.; Qi, Y.; Konoplev, S.; Su, X.; DiNardo, C.D.; Daver, N.; Majeti, R.; Andreeff, M. Efficacy of novel glutaminase inhibitor CB-839 in acute myeloid leukemia. Blood 2014, 124, 3763
95. Thomas, A.G.; Rojas, C.; Tanega, C.; Shen, M.; Simeonov, A.; Boxer, M.B.; Auld, D.S.; Ferraris, D.V.; Tsukamoto, T.; Slusher, B.S. Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors. Biochem. Biophys. Res. Commun. 2013, 438, 243–248.
96. Crosby, H.; Ihnat, M.; Miller, K. Evaluating the toxicity of the analgesic glutaminase inhibitor 6-Diazo-5-oxo-L-norleucine in vitro and on rat dermal skin fibroblasts. MOJ Toxicol. 2015, doi:10.15406/mojt.2015.01.00005
97. Yoshioka, K.; Takehara, H.; Okada, A.; Komi, N. Glutamine antagonist with diet deficient in glutamine and aspartate reduce tumor growth. Tokushima J. Exp. Med. 1992, 39, 69–76.
98. Shapiro, R.A.; Clark, V.M.; Curthoys, N.P. Inactivation of rat renal phosphate-dependent glutaminase with 6-diazo-5-oxo-L-norleucine. Evidence for interaction at the glutamine binding site. J. Biol. Chem. 1979, 254, 2835–2838.
99. Rosenfeld, H.; Roberts, J. Enhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-L-norleucine and acivicin in cell culture by glutaminase-asparaginase. Cancer Res. 1981, 41, 1324–1328.
100. Maeda, K.; Nakajima, Y.; Motoyama, T.; Kitou, Y.; Kosaki, T.; Saito, T.; Nishiuchi, T.; Kanamaru, K.; Osada, H.; Kobayashi, T et al. Effects of acivicin on growth, mycotoxin production and virulence of phytopathogenic fungi. Lett. Appl. Microbiol. 2014, 59, 377–383.
101. Allen, L.; Meck, R.; Yunis, A. The inhibition of γ-glutamyl transpeptidase from human pancreatic carcinoma cells by (α S,5S)-α-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125; NSC-163501). Res. Commun. Chem. Pathol. Pharmacol. 1980, 27, 175–182.
102. Hidalgo, M.; Rodriguez, G.; Kuhn, J.G.; Brown, T.; Weiss, G.; MacGovren, J.P.; von Hoff, D.D.; Rowinsky, E.K. A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies. Clin. Cancer Res. 1998, 4, 2763–2770.
103. Karunakaran, S.; Ramachandran, S.; Coothankandaswamy, V.; Elangovan, S.; Babu, E.; Periyasamy-Thandavan, S.; Gurav, A.; Gnanaprakasam, J.P.; Singh, N.; Schoenlein, P.V et al. SLC6A14 (ATB0,+) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer. J. Biol. Chem. 2011, 286, 31830–31838.
104. Butler, E.B.; Zhao, Y.; Muñoz-Pinedo, C.; Lu, J.; Tan, M. Stalling the engine of resistance: Targeting cancer metabolism to overcome therapeutic resistance. Cancer Res. 2013, 73, 2709–2717.
105. Whitelaw, B.S.; Robinson, M.B. Inhibitors of glutamate dehydrogenase block sodium-dependent glutamate uptake in rat brain membranes. Front. Endocrinol. 2013, 4, 123.
106. Yang, C.; Ko, B.; Hensley, C.T.; Jiang, L.; Wasti, A.T.; Kim, J.; Sudderth, J.; Calvaruso, M.A.; Lumata, L.; Mitsche, M et al. Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. Mol. Cell 2014, 56, 414–424.
107. Li, C.; Li, M.; Chen, P.; Narayan, S.; Matschinsky, F.M.; Bennett, M.J.; Stanley, C.A.; Smith, T.J. Green tea polyphenols control dysregulated glutamate dehydrogenase in transgenic mice by hijacking the ADP activation site. J. Biol. Chem. 2011, 286, 34164–34174.
108. Willems, L.; Jacque, N.; Jacquel, A.; Neveux, N.; Maciel, T.T.; Lambert, M.; Schmitt, A.; Poulain, L.; Green, A.S.; Uzunov, M et al. Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood 2013, 122, 3521–3532.
109. Avramis, V.I.; Martin-Aragon, S.; Avramis, E.V.; Asselin, B.L. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: Simulations of erwinase population PK-PD models. Anticancer Res. 2007, 27, 2561–2572.
110. Jover-Cobos, M.; Noiret, L.; Lee, K.; Sharma, V.; Habtesion, A.; Romero-Gomez, M.; Davies, N.; Jalan, R. Ornithine phenylacetate targets alterations in the expression and activity of glutamine synthase and glutaminase to reduce ammonia levels in bile duct ligated rats. J. Hepatol. 2014, 60, 545–553.
111. Ytrebo, L.M.; Kristiansen, R.G.; Maehre, H.; Fuskevag, O.M.; Kalstad, T.; Revhaug, A.; Cobos, M.J.; Jalan, R.; Rose, C.F. L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure. Hepatology 2009, 50, 165–174.
112. Thomas, A.G.; O’Driscoll, C.M.; Bressler, J.; Kaufmann, W.; Rojas, C.J.; Slusher, B.S. Small molecule glutaminase inhibitors block glutamate release from stimulated microglia. Biochem. Biophys. Res. Commun. 2014, 443, 32–36.
113. Matés, J.M.; Segura, J.A.; Martín-Rufián, M.; Campos-Sandoval, J.A.; Alonso, F.J.; Márquez, J. Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer. Curr. Mol. Med. 2013, 13, 514–534.
114. Elgadi, K.M.; Meguid, R.A.; Qian, M.; Souba, W.W.; Abcouwer, S.F. Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. Physiol. Genom. 1999, 1, 51–62.
115. Shukla, K.; Ferraris, D.V.; Thomas, A.G.; Stathis, M.; Duvall, B.; Delahanty, G.; Alt, J.; Rais, R.; Rojas, C.; Gao, P. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl) ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J. Med. Chem. 2012, 55, 10551–10563.
116. Liu, J.; Zhang, C.; Lin, M.; Zhu, W.; Liang, Y.; Hong, X.; Zhao, Y.; Young, K.H.; Hu, W.; Feng, Z. Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma. Oncotarget 2014, 5, 2635–2647.
117. Campos-Sandoval, J.; Alonso, F.; Segura, J.; Manzanares, E.; Perez-Gomez, C.; Ruiz-Sánchez, P.; González, M.; Márquez, J.; Matés, J. Co-expression of glutaminase K and L isoenzymes in human tumour cells. Biochem. J. 2005, 386, 535–542.
118. Lobo, C.; Ruiz-Bellido, M.; Aledo, J.; Marquez, J.; Núñez, D.C.I.; Alonso, F. Inhibition of glutaminase expression by antisense mRNA decreases growth and tumourigenicity of tumour cells. Biochem. J. 2000, 348, 257–261.
119. Seltzer, M.J.; Bennett, B.D.; Joshi, A.D.; Gao, P.; Thomas, A.G.; Ferraris, D.V.; Tsukamoto, T.; Rojas, C.J.; Slusher, B.S.; Rabinowitz, J.D. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010, 70, 8981–8987.
120. Xiang, Y.; Stine, Z.E.; Xia, J.; Lu, Y.; O’Connor, R.S.; Altman, B.J.; Hsieh, A.L.; Gouw, A.M.; Thomas, A.G.; Gao, P et al. Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J. Clin. Investig. 2015, 125, 2293–306.
121. Campos-Sandoval, J.A.; de la Oliva, A.R.L.; Lobo, C.; Segura, J.A.; Matés, J.M.; Alonso, F.J.; Márquez, J. Expression of functional human glutaminase in baculovirus system: Affinity purification, kinetic and molecular characterization. Int. J. Biochem. Cell Biol. 2007, 39, 765–773.
122. Engler, J.; Gottesman, J.; Harkins, J.; Urazaev, A.; Lieberman, E.; Grossfeld, R. Properties of glutaminase of crayfish CNS: Implications for axon-glia signaling. Neuroscience 2002, 114, 699–705.
123. Velletri, T.; Romeo, F.; Tucci, P.; Peschiaroli, A.; Annicchiarico-Petruzzelli, M.; Niklison-Chirou, M.V.; Amelio, I.; Knight, R.A.; Mak, T.W.; Melino, G. GLS2 is transcriptionally regulated by p73 and contributes to neuronal differentiation. Cell Cycle 2013, 12, 3564–3573.
124. Qie, S.; Chu, C.; Li, W.; Wang, C.; Sang, N. ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation. J. Cell. Biochem. 2014, 115, 498–509.
125. Reynolds, M.R.; Lane, A.N.; Robertson, B.; Kemp, S.; Liu, Y.; Hill, B.G.; Dean, D.C.; Clem, B.F. Control of glutamine metabolism by the tumor suppressor Rb. Oncogene 2014, 33, 556–566.
126. Zhao, L.; Huang, Y.; Tian, C.; Taylor, L.; Curthoys, N.; Wang, Y.; Vernon, H.; Zheng, J. Interferon-α regulates glutaminase 1 promoter through STAT1 phosphorylation: Relevance to HIV-1 associated neurocognitive disorders. PLoS ONE 2012, 7, e32995.
127. Jeong, S.M.; Xiao, C.; Finley, L.W.; Lahusen, T.; Souza, A.L.; Pierce, K.; Li, Y.-H.; Wang, X.; Laurent, G.; German, N.J. SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell 2013, 23, 450–463.
128. Emadi, A.; Jun, S.A.; Tsukamoto, T.; Fathi, A.T.; Minden, M.D.; Dang, C.V. Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Exp. Hematol. 2014, 42, 247–251.
129. Dutta, P.; Le, A.; Vander Jagt, D.L.; Tsukamoto, T.; Martinez, G.V.; Dang, C.V.; Gillies, R.J. Evaluation of LDH-A and glutaminase inhibition in vivo by hyperpolarized 13C-pyruvate magnetic resonance spectroscopy of tumors. Cancer Res. 2013, 73, 4190–4195.
130. Li, J.; Csibi, A.; Yang, S.; Hoffman, G.R.; Li, C.; Zhang, E.; Yu, J.J.; Blenis, J. Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells. Proc. Natl. Acad. Sci. USA 2015, 112, E21–E29.
131. Katt, W.P.; Antonyak, M.A.; Cerione, R.A. Simultaneously targeting tissue transglutaminase and kidney type glutaminase sensitizes cancer cells to acid toxicity and offers new opportunities for therapeutic intervention. Mol. Pharm. 2014, 12, 46–55.
132. Simpson, N.E.; Tryndyak, V.P.; Pogribna, M.; Beland, F.A.; Pogribny, I.P. Modifying metabolically sensitive histone marks by inhibiting glutamine metabolism affects gene expression and alters cancer cell phenotype. Epigenetics 2012, 7, 1413–1420.
133. Tanaka, K.; Sasayama, T.; Irino, Y.; Takata, K.; Nagashima, H.; Masui, K.; Gini, B.; Yang, H.; Mischel, P.S.; Kohmura, E. NT-39glutaminase-mediated metabolic pathway involves glioblastoma resistance to mtor-targeted therapies. Neuro-Oncology 2014, 16, v167.
134. Tanaka, K.; Sasayama, T.; Irino, Y.; Takata, K.; Nagashima, H.; Satoh, N.; Kyotani, K.; Mizowaki, T.; Imahori, T.; Ejima, Y. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. J. Clin. Investig. 2015, 125, 1591–1602.
135. Terunuma, A.; Putluri, N.; Mishra, P.; Mathé, E.A.; Dorsey, T.H.; Yi, M.; Wallace, T.A.; Issaq, H.J.; Zhou, M.; Killian, J.K. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J. Clin. Investig. 2014, 124, 398–412.
136. Santana, S.M.; Antonyak, M.A.; Cerione, R.A.; Kirby, B.J. Cancerous epithelial cell lines shed extracellular vesicles with a bimodal size distribution that is sensitive to glutamine inhibition. Phys. Biol. 2014, 11, 065001.
137. Parlati, F.; Demo, S.; Gross, M.; Janes, J.; Lewis, E.; MacKinnon, A.; Rodriguez, M.; Shwonek, P.J.; Wang, T.; Yang, J. CB-839, a novel potent and selective glutaminase inhibitor, has broad antiproliferative activity in cell lines derived from both solid tumors and hematological malignancies. Cancer Res. 2014, 74, 1416.
138. Das, D.S.; Ravillah, D.; Ray, A.; Song, Y.; Munshi, N.C.; Richardson, P.G.; Chauhan, D.; Anderson, K.C. Anti-myeloma activity of a novel glutaminase inhibitor CB-839. Blood 2014, 124, 3439.
139. Jacque, N.; Ronchetti, A.M.; Larrue, C.; Meunier, G.; Birsen, R.; Willems, L.; Saland, E.; Decroocq, J.; Maciel, T.T.; Lambert, M. Targeting glutaminolysis has anti-leukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. Blood 2015, 126, 1346–1356.
140. Xiang, L.; Xie, G.; Liu, C.; Zhou, J.; Chen, J.; Yu, S.; Li, J.; Pang, X.; Shi, H.; Liang, H. Knock-down of glutaminase 2 expression decreases glutathione, NADH, and sensitizes cervical cancer to ionizing radiation. Biochim. Biophys. Acta 2013, 1833, 2996–3005.
141. Lee, Y.Z.; Yang, C.W.; Chang, H.Y.; Hsu, H.Y.; Chen, I.S.; Chang, H.S.; Lee, C.H.; Lee, J.C.; Kumar, C.R.; Qiu, Y.Q et al. Discovery of selective inhibitors of Glutaminase-2, which inhibit mTORC1, activate autophagy and inhibit proliferation in cancer cells. Oncotarget 2014, 5, 6087–6101.
142. Dang, C.V.; Le, A.; Gao, P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin. Cancer Res. 2009, 15, 6479–6483.